Purdue Pharma vow not to profit from fast tracked opioid overdose antidote
March 18, 2019Sales and Marketing FDA, OxyContin, Purdue Pharma, nalmefene hydrochloride, opioids
The FDA has granted OxyContin drugmaker Purdue Pharma, fast track designation for opioid overdose antidote nalmefene hydrochloride (HCl) injection. However, …
Merck KGaA enters drug discovery partnership with AI firm Itkos
March 15, 2019Medical Communications, Research and Development AI, Merck, Merck KGaA, drug discovery, pharma
Merck KGaA and artificial intelligence (AI) firm Iktos have entered into a partnership, the pair have announced, to leverage the …
National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
Sandoz CEO Richard Francis to step down
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Roche scores two EU approvals in haemophilia and rare autoimmune disease
March 15, 2019Medical Communications EC, EU, Europe, Roche, haemophilia, rare diseases
The European Commission (EC) has approved Roche’s haemophilia treatment Hemlibra (emicizumab). The approval comes as the EC approved Roche’s MabThera …
MSD’s Keytruda/chemo combo nabs EU approval in first-line metastatic squamous lung cancer
March 15, 2019Medical Communications, Sales and Marketing Cancer, MSD, NSCLC, keytruda, lung cancer, pharma
MSD’s anti-PD-L1 therapy Keytruda (pembrolizumab) has been awarded marketing authorisation in Europe for the first-line treatment of adult patients with …
Top Ten most popular articles on Pharmafile.com this week!
March 15, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Acadia Pharmaceuticals, FDA, Sandoz, brexit, genomics, pharma, pharmacovigilance, top 10
The US Department of Justice has launched an investigation into the sales and marketing practices of San Diego firm Acadia …
Pfizer CEO Ian Read’s pay packet cut from $27.9m to $19.5m
March 15, 2019Medical Communications CEO, Ian Read, Pfizer, compensation, pay packet, salary
Ian Read has seen his total compensation cut from a sum of $27.9 million in 2018 to $19.5 million this …
Roche and Chugai’s Hemlibra scoops up EU approval in the prevention of severe haemophilia A without factor VIII inhibitors
March 14, 2019Sales and Marketing Chugai, Hemlibra, Roche, haemophilia, pharma
Roche has announced along with its partner Chugai that Hemlibra (emicizumab) has secured approval from the European Commission as a …
Celgene’s Abraxane combo flops in phase 3 cancer trials
March 14, 2019Research and Development Abraxane, Celgene, clinical trials, pharma, trials
Celgene’s Abraxane, in combination gemcitabine, has failed to meet its primary endpoint in a pivotal Phase 3 trial of patients …
New class of drugs offer alternative to statins
March 14, 2019Research and Development cholesterol, health, imperial college london, research, statins
A new class of cholesterol lowering drugs may help patients who are unable to take statins, according to a study …
Sandoz CEO Richard Francis to step down
March 14, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing CEO, Novartis, Sandoz, appointment, pharma
Richard Francis is set to step down his role as Chief Executive of Novartis’ generics arm Sandoz after five years’ …
Califonia court rules J&J must pay woman with mesothelioma $29 million
March 14, 2019Medical Communications, Sales and Marketing
A California jury has ordered American healthcare conglomerate Johnson & Johnson to pay more than $29 million to a woman …
National Cancer Institute Director Ned Sharpless to become interim FDA Commissioner
March 13, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing FDA, Ned Sharpless, Scott Gottlieb, appointment, pharma
Following the surprise resignation of current FDA Commissioner Dr Scott Gottlieb a week earlier, Dr Norman ‘Ned’ Sharpless, Director of …
Janssen’s ulcerative colitis treatment shows positive results in phase 3 trials
March 13, 2019Manufacturing and Production, Research and Development Jansenn, Stelara, phase 3 trials, ulcerative colitis
Janssen’s ulcerative colitis treatment, Stelara (ustekinumab subcutaneous) has shown positive results as maintenance therapy in phase 3 trials. The study …
Lilly’s Cyramza hits Phase 3 endpoint in first-line metastatic lung cancer treatment
March 13, 2019Research and Development Cancer, Eli Lilly, cyramza, lung cancer, pharma
Eli Lilly’s vascular endothelial growth factor (VEGF) Receptor 2 antagonist Cyramza (ramucirumab) has succeeded in hitting its primary endpoint at …
Healthcare industry could take up to five years to stabilise after no-deal Brexit
March 13, 2019Manufacturing and Production, Medical Communications, Research and Development GlobalData, analysis, brexit, no-deal Brexit, surveys
The healthcare industry could take up to five years to stabilise in the event of a no-deal Brexit, according to …
FDA approve valsartan generic after shortages of supply
March 13, 2019Manufacturing and Production, Research and Development FDA, blood pressure drugs, cardiovascular, generic, valsartan
The FDA has approved a new generic version of blood pressure drug valsartan. The approval comes amid shortages in supply …
Innate Pharma hires Jennifer Butlers to lead commercialisation of leukaemia drug Lumoxiti
March 12, 2019Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing
French company Innate Pharma have announced the appointment of Jennifer Butler to the position of Executive Vice President and General …
FDA expands Dupixent indication to include moderate-to-severe atopic dermatitis in adolescent patients
March 12, 2019Manufacturing and Production, Sales and Marketing Dupixent, Regeneron, Sanofi, pharma
Partners Sanofi and Regeneron have both revealed that their jointly developed drug Dupixent (dupilumab) has been authorised by the FDA …
Latest content
Major funding opportunity opens for early cancer diagnostics
Androlabs receives UK authorisation for new Testavan presentation
CEPI backs African-led Bundibugyo Ebola vaccine development
Cytomos appoints life sciences executive to board
